Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$150.30 USD

150.30
680,430

+0.34 (0.23%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Cardinal Health (CAH) Streamlines Operation With New Structure

Cardinal Health's (CAH) new reporting structure is likely to streamline operations, providing better visibility of growth areas. At-home solutions and OptiFreight Logistics are possibly the key value creators.

Nalak Das headshot

5 Mid-Cap Stocks to Buy in a Volatile January

We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.

Here's Why Investors Should Retain Integra (IART) Stock Now

Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.

Medtronic (MDT) Wins CE Mark for MiniMed 780G With Simplera Sync

Medtronic (MDT) secures the CE Mark for the MiniMed 780G system with the disposable, all-in-one Simplera Sync CGM.

Benjamin Rains headshot

How to Find Great Momentum Stocks to Buy in 2024

The screen we explore today aims to find Zacks Rank #1 (Strong Buy) stocks that boast strong upward price momentum to help investors buy potential winners in January and throughout 2024.

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.

QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.

SenesTech's (SNES) New Partnership to Broaden Evolve's Scope

The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues

Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.

DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.

Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Best Growth Stocks to Buy for January 9th

EG, BROS and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 9, 2024.

Illumina (ILMN) Extends Partnership to Advance Cancer Test

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.

Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt

Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.

Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes

Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.

Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales

Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.

Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence

Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.